2016
DOI: 10.1038/ncomms13100
|View full text |Cite
|
Sign up to set email alerts
|

Selective removal of deletion-bearing mitochondrial DNA in heteroplasmic Drosophila

Abstract: Mitochondrial DNA (mtDNA) often exists in a state of heteroplasmy, in which mutant mtDNA co-exists in cells with wild-type mtDNA. High frequencies of pathogenic mtDNA result in maternally inherited diseases; maternally and somatically acquired mutations also accumulate over time and contribute to diseases of ageing. Reducing heteroplasmy is therefore a therapeutic goal and in vivo models in post-mitotic tissues are needed to facilitate these studies. Here we describe a transgene-based model of a heteroplasmic … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
90
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
5
2
2

Relationship

0
9

Authors

Journals

citations
Cited by 89 publications
(94 citation statements)
references
References 70 publications
3
90
0
Order By: Relevance
“…1). The balance of mitochondrial fusion and ssion is critical for the normal physiological function of cells, which contribute to regulation of mitochondrial morphology [11,12] , exchange of content [13,14] , maintenance of mitochondrial DNA (mtDNA) [9,15] and clearance of damaged mitochondria [16,17] . Defect and damage in mitochondrial dynamics have resulted in numerous human diseases, such as Charcot-Marie-Tooth disease type 2A (CMT2A) [18,19] , Multiple symmetric lipomatosis [20,21] , Dominant optic atrophy [22] , Microcephaly and Optic atrophy [23] .…”
Section: Introductionmentioning
confidence: 99%
“…1). The balance of mitochondrial fusion and ssion is critical for the normal physiological function of cells, which contribute to regulation of mitochondrial morphology [11,12] , exchange of content [13,14] , maintenance of mitochondrial DNA (mtDNA) [9,15] and clearance of damaged mitochondria [16,17] . Defect and damage in mitochondrial dynamics have resulted in numerous human diseases, such as Charcot-Marie-Tooth disease type 2A (CMT2A) [18,19] , Multiple symmetric lipomatosis [20,21] , Dominant optic atrophy [22] , Microcephaly and Optic atrophy [23] .…”
Section: Introductionmentioning
confidence: 99%
“…If mitophagy is able to change mean heteroplasmy, then a neutral genetic model appears to be inappropriate, as mutants experience a higher rate of degradation. Biological examples of non-neutral behavior include the observation that the PINK1/Parkin pathway can select against deleterious mtDNA mutations in vitro (Suen et al 2010) and in vivo (Kandul et al 2016), as has repression of the mTOR pathway via treatment with rapamycin (Dai et al 2013;Kandul et al 2016). However, the necessity of performing a genetic/pharmacological intervention to clear mutations via this pathway suggests that the ability of tissues to selectively remove mitochondrial mutants under physiological conditions is weak.…”
Section: Discussionmentioning
confidence: 99%
“…If we assume that fusion is selective in favor of wild-type mtDNAs, which appears to be the case at least for some mutations under therapeutic conditions (Suen et al 2010;Kandul et al 2016), we predict that a balance between fusion and fission is the most effective means of removing mutant mtDNAs (see below), perhaps explaining why mitochondrial networks are often observed to exist as balanced between mitochondrial fusion and fission (Sukhorukov et al 2012;Zamponi et al 2018). In contrast, if selective mitophagy pathways are induced then promoting fragmentation is predicted to accelerate the clearance of mutants (see below).…”
Section: Control Strategies Against Mutant Expansionsmentioning
confidence: 99%
“…If mitophagy is able to change mean heteroplasmy, then a neutral genetic model appears to be inappropriate, as mutants experience a higher rate of degradation. Stimulation of the PINK1/Parkin pathway has been shown to select against deleterious mtDNA mutations in vitro (Suen et al, 2010) and in vivo (Kandul et al, 2016), as has repression of the mTOR pathway via treatment with rapamycin (Dai et al, 2013;Kandul et al, 2016). However, the necessity of performing a genetic/pharmacological intervention to clear mutations via this pathway suggests that the ability of tissues to selectively remove mitochondrial mutants under physiological conditions is weak.…”
Section: Discussionmentioning
confidence: 99%